Barmherzige Brueder Trier gGmbH

At Barmherzige Brueder Trier gGmbH, the cardiovascular diseases portfolio includes studies in atrial fibrillation, acute myocardial infarction, hypertension, and broader atherosclerotic cardiovascular disease. These trials are mainly designed to test new treatment strategies, improve protection against clotting and bleeding complications, and reduce the risk of major heart and stroke events.

• Atrial fibrillation after coronary procedures and the balance between clot prevention and bleeding risk
• Heart attack and recovery-focused therapies aimed at improving cardiac outcomes
• Cardiovascular risk reduction in people with established heart and vessel disease

The site’s Herzzentrum Trier Innere Medizin III - Kardiologie is active in research that may help refine everyday treatment decisions for patients with complex cardiovascular conditions.

A major part of the research program focuses on neoplasms, especially acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma, and several solid tumors including colorectal cancer, lung cancer, and prostate cancer. The studies are largely aimed at comparing new combinations of therapy, improving survival, and finding better options for patients with difficult-to-treat or newly diagnosed cancers.

• Acute myeloid leukemia and treatment approaches for newly diagnosed patients
• Bladder cancer and muscle-invasive urothelial carcinoma with a focus on better cancer control
• Colorectal, rectal, and gastroesophageal junction cancer studies exploring improved pre- and post-surgery care

This is a strong area of oncology research at the Trier site, with trials examining both standard treatment improvement and newer targeted or immune-based approaches.

The site also contributes to studies in digestive system diseases, immune system diseases, and kidney-related conditions such as IgA nephropathy and chronic kidney disease. These trials are generally intended to slow disease progression, preserve organ function, and evaluate whether new therapies can offer better long-term control than current standard care.

• IgA nephropathy with emphasis on kidney protection and proteinuria reduction
• Chronic kidney disease linked to broader cardiometabolic risk
• Immune-mediated inflammation affecting organs such as the kidneys and blood vessels

Research in this area reflects a growing interest in conditions where immune activity and organ damage overlap, creating opportunities for more personalized treatment.

Clinical trials at the site include work in nervous system diseases, particularly acute ischemic stroke and early symptomatic Alzheimer’s disease. The purpose of these studies is to improve recovery after stroke and to test therapies that may slow cognitive decline in people with early memory and thinking problems.

• Acute ischemic stroke focused on better functional recovery and safety
• Early symptomatic Alzheimer’s disease with the goal of delaying progression
• Neurologic outcomes that matter to independence and daily function

These trials show that the site is involved not only in cardiovascular care, but also in research addressing major age-related brain disorders.

Another important theme is research into immune system processes and inflammatory diseases such as giant cell arteritis. The trials are designed to test whether new anti-inflammatory therapies can better prevent relapse, improve disease control, and reduce reliance on long-term steroid treatment.

• Giant cell arteritis and relapse prevention
• Inflammation-driven vascular disease requiring long-term monitoring
• Therapies aimed at improving control while reducing treatment burden

This area adds to the site’s broader profile in diseases where immune activity has a direct impact on blood vessels and overall health.

The clinical trial portfolio includes male urogenital diseases such as prostate cancer, metastatic castration-sensitive prostate cancer, and urothelial carcinoma. The main goal is to assess new treatment combinations and sequencing strategies that may improve cancer control and delay progression in patients with advanced disease.

• Prostate cancer across localized and metastatic settings
• Bladder and urothelial cancers with a focus on treatment effectiveness
• Therapies designed to improve survival and disease-free outcomes

At this hospital-based research site, urologic oncology is closely linked with broader cancer care and multidisciplinary treatment planning.